Skip to content

Catecholamine Blockade Post-burn

Clinical and Molecular Effects of Catecholamine Blockade Post-burn

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01299753
Enrollment
80
Registered
2011-02-18
Start date
2011-02-28
Completion date
2023-12-31
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burns

Brief summary

Severe burn is associated with a wide array of stress, metabolic, and physiologic processes in an attempt to restore homeostasis. The catecholamine induced stress response following severe burns is particularly exaggerated and manifests detrimentally as inflammation, insulin resistance, hypermetabolism, and associated profound protein catabolism. The investigators hypothesize that catecholamine blockade will lead to restored IR signaling and result in improved post-burn morbidity. The investigators will further determine the molecular mechanisms mediating these effects.

Interventions

DRUGplacebo

identically packed placebo

DRUGpropranolol

20-40 mg q6-8h

Sponsors

Sunnybrook Health Sciences Centre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patients between 18 and 90 years of age * \>25% TBSA burn

Exclusion criteria

* Death upon admission * Decision not to treat due to burn injury severity

Design outcomes

Primary

MeasureTime frameDescription
Perform oral glucose tolerance testConduct at week 1 post admissionStandard fasting oral glucose tolerance test with an intake of 75 g of glucose. Subsequent measurements (in mg/dl) of glucose in blood, insulin and c-peptide will be conducted over 2 hours.

Secondary

MeasureTime frameDescription
Measure concentrations of serum cytokinesweekly until discharge (1-4 months post admission depending on severity)Inflammatory response will be assessed by measuring the concentrations (pg/ml) of a panel of serum cytokines (IL-1, IFN, TNF etc.) using the Bio-Plex 17-Plex Suspension assay.
Record the episodes of Pneumoniadaily until discharge (1-4 months post admission depending on severity)Pneumonia is defined by the following criteria: new progressive and persistent infiltrate, consolidation, or cavitations, in light of the baseline evaluation for inhalational injury on chest X-ray, along with signs of sepsis, worsening gas exchange (decreased P/F ratio), increased O2, and change in the sputum, e.g. purulent or increased sputum production.
Record the episodes of sepsisdaily until discharge (1-4 months post admission depending on severity of injury)Patients are evaluated daily and the number of episodes of sepsis or bloodstream infection will be recorded
Measure the levels of activated signaling proteins using protein blottingassess at 1st operation (week 1-2 post admission on average) and 3rd operation (week 3-4 post admission on average)The level of activation of a protein signaling cascade (fold change compared to control), as indicated by the amount of phosphorylated protein substrates (e.g. p-Akt/Akt), will be measured in tissue obtained at operation using protein blotting techniques in the laboratory.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026